# Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in Islamabad

> **NCT05428592** · PHASE3 · UNKNOWN · sponsor: **AIM Vaccine Co., Ltd.** · enrollment: 1100 (estimated)

## Conditions studied

- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** LVRNA009
- **BIOLOGICAL:** CoronaVac®

## Key facts

- **NCT ID:** NCT05428592
- **Lead sponsor:** AIM Vaccine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04
- **Primary completion:** 2023-10
- **Final completion:** 2024-10
- **Target enrollment:** 1100 (ESTIMATED)
- **Last updated:** 2023-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05428592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05428592, "Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in Islamabad". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05428592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*